Electrophysiologic Measures of Treatment Response in Alzheimer Disease
Phase 4
Completed
- Conditions
- Alzheimer Disease
- Registration Number
- NCT00018278
- Lead Sponsor
- US Department of Veterans Affairs
- Brief Summary
The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the electrophysiological biomarkers of cholinergic therapy response in Alzheimer's disease as studied in NCT00018278?
How do cholinesterase inhibitors and transdermal nicotine compare in improving verbal memory ERPs in Alzheimer patients?
What molecular mechanisms underlie the effects of cholinergic therapy on cognitive function in Alzheimer's disease?
Are there specific ERP patterns that predict clinical outcomes for Alzheimer's patients on cholinergic treatments?
What adverse events are associated with transdermal nicotine use in Alzheimer's disease trials and how are they managed?
Trial Locations
- Locations (1)
Department of Veterans Affairs
🇺🇸San Diego, California, United States
Department of Veterans Affairs🇺🇸San Diego, California, United States